India approves DNA Plasma Covid19 vaccine for adolescents
The three-dose ZyCoV-D vaccine prevented symptomatic disease in 66% of those vaccinated, according to an interim study quoted by the vaccine maker Cadila Healthcare. The firm plans to make up to 120 million doses of India’s second home-grown vaccine every year.
India’s drug regulator on Friday approved Zydus Cadila’s three-dose COVID-19 DNA vaccine for emergency use in adults and children aged 12 years and above, bringing in the sixth vaccine authorised for use in the country.
India has so far given more than 570 million doses of three previously approved vaccines – Covishield, Covaxin and Sputnik V. About 13% of adults have been fully vaccinated and 47% have received at least one shot since the beginning of the drive in January.
Zydus Cadila had earlier said that they can launch their three-dose plasmid DNA Covid-19 vaccine within two months of receiving the approval. ZyCoV-D is the world’s first plasmid DNA vaccine against the coronavirus. It uses a section of genetic material from the virus that gives instructions as either DNA or RNA to make the specific protein that the immune system recognises and responds to.
ZyCov-D, which is being developed in partnership with the Department of Biotechnology and the Indian Council of Medical Research (ICMR), can be stored at 2-8 degrees Celsius and at 25 degrees Celsius for up to three months.